Kindred Biosciences Inc

NASDAQ:KIN   3:59:40 PM EDT
4.04
-0.02 (-0.49%)
Products, Strategic Combinations, Expansion

Centaur Biopharmaceutical Services Announces Expansion Of Manufacturing Agreement With Vaxart For Covid-19 And Other Vaccine Candidates

Published: 10/07/2020 12:26 GMT
Kindred Biosciences Inc (KIN) - Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement With Vaxart for Covid-19 and Other Vaccine Candidates.
Centaur Biopharmaceutical Services - Will Manufacture Vaxart's Oral Vaccine for Covid-19 and Other Vaccine Candidates.
Centaur Biopharmaceutical Services - California Plant Will Be Responsible for Scaling Covid-19 Clinical Trial Material Into Mid-size Bioreactors.
Centaur Biopharmaceutical Services - Kansas Plant Will Be Responsible for Manufacturing at 2000l Scale in Its Single Use Bioreactors.